Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Michał J Kubisa, Mateusz P Jezewski, Aleksandra Gasecka, Jolanta M Siller-Matula & Marek Postuła. (2018) Ticagrelor – toward more efficient platelet inhibition and beyond. Therapeutics and Clinical Risk Management 14, pages 129-140.
Read now
Read now
Gian Marco Rosa, Daniele Bianco, Alberto Valbusa, Laura Massobrio, Francesco Chiarella & Claudio Brunelli. (2016) Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia. Expert Opinion on Drug Metabolism & Toxicology 12:12, pages 1491-1502.
Read now
Read now
Articles from other publishers (11)
Mario Cazzola, Paola Rogliani, Josuel Ora, Luigino Calzetta & Maria Gabriella Matera. (2023) Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences. Therapeutic Advances in Chronic Disease 14, pages 204062232311715.
Crossref
Crossref
Ming Yue, Mengjiao Hu, Fangda Fu, Hongfeng Ruan & Chengliang Wu. (2022) Emerging Roles of Platelets in Allergic Asthma. Frontiers in Immunology 13.
Crossref
Crossref
Alicja Krakowiak, Jakub Kuleta, Iwona Plech, Maciej Zarębiński, Małgorzata Wojciechowska, Dominik Wretowski & Agnieszka Cudnoch-Jędrzejewska. (2020) Ticagrelor-Related Severe Dyspnoea: Mechanisms, Characteristic Features, Differential Diagnosis and Treatment. Clinical Medicine Insights: Case Reports 13, pages 117954762095663.
Crossref
Crossref
Vijay Kunadian, Nina Wilson, Deborah D. Stocken, Hani Ali, Elaine McColl, Graham Burns, Nicola Howe, Andrew Fisher & Anthony De Soyza. (2019) Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial. ERJ Open Research 5:3, pages 00110-2019.
Crossref
Crossref
Lyn Rosenbrier Ribeiro & R. Ian Storer. (2017) A semi-quantitative translational pharmacology analysis to understand the relationship between in vitro ENT1 inhibition and the clinical incidence of dyspnoea and bronchospasm. Toxicology and Applied Pharmacology 317, pages 41-50.
Crossref
Crossref
Martin Unverdorben, Guido Parodi, Massimo Pistolesi & Robert F. Storey. (2016) Dyspnea related to reversibly-binding P2Y12 inhibitors: A review of the pathophysiology, clinical presentation and diagnostics. International Journal of Cardiology 202, pages 167-173.
Crossref
Crossref
Renli Teng. (2015) Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update. Clinical Pharmacokinetics 54:11, pages 1125-1138.
Crossref
Crossref
Gianluca Campo, Rita Pavasini, Simone Biscaglia, Marco Contoli & Claudio Ceconi. (2015) Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease. European Heart Journal - Cardiovascular Pharmacotherapy 1:3, pages 205-211.
Crossref
Crossref
Paul P. Dobesh & Julie H. Oestreich. (2014) Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34:10, pages 1077-1090.
Crossref
Crossref
Daniel Caldeira, Fausto J. Pinto & Joaquim J. Ferreira. (2014) Dyspnea and Reversibility Profile of P2Y12 Antagonists: Systematic Review of New Antiplatelet Drugs. American Journal of Cardiovascular Drugs 14:4, pages 303-311.
Crossref
Crossref
S. Möhlenkamp, G. Weinreich, T. Neumann, T. Voshaar & H. Teschler. (2014) Medikamentöse Therapie von Herz- und LungenerkrankungenMedical therapy of heart and lung diseases. Herz 39:1, pages 15-24.
Crossref
Crossref